Latest Ranibizumab Stories
TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc.
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
TARRYTOWN, N.Y. and BERLIN, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc.
Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) â€“ Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.
Newer treatments for age-related macular degeneration (AMD)â€”including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye diseaseâ€”do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies.
Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
BRISBANE, Calif., Sept. 14 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced that Quinton Oswald has joined the company as Chief Executive Officer. Mr.
INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
INCLINE VILLAGE, Nev., June 15 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30, 2010 of approximately $120 million, as compared with actual results of $125.9 million for the second quarter of 2009.
- a meat pie that is usually eaten at Christmas in Quebec